According to people familiar with the matter, the value of the laf of the label side of the radical investor has occupied the shares of Becton Dickinson and is promoting this $ 7.2 billion medical technology company to sell its life science department.
It is said that hedge funds have met with the group's management team and sent a letter to the board asking the company to sell or disassemble the unit, which makes the products used in clinical and research laboratories. The size of the bet on the field is unclear.
Becton Dickinson's stock performance is not good and the Standards Poore 500 index in recent years has only obtained 4.4 % of the shares in the past year, while the S & P 500 index has increased by nearly 22 %. Becton Dickinson's stock has risen by 3 % at the stock price of Becton Dickinson. After the shares on the side side, the pre -sale transaction was exposed.
Independent people say that the company headquarters in New Jersey has cooperated with consultants and can conduct potential derivatives from the life science department between 33 billion to 35 billion US dollars according to the valuation of industry counterparts. Bloomberg first reported the Becton Dickinson recruitment consultant.
For the people, other shareholders have also begun to incite the management and board of Dickinson to demolish the life science department, but Starboard's arrival of the company's shareholder registration may increase the urgency of this process. The unit generated $ 5.2 billion in the year at the end of September 2024, accounting for about a quarter of the total revenue of Becton Dickinson.
Becton Dickinson refuses to comment. There is no immediately responding to the commentary request.
Analysts of investment banks have pointed out in recent months that Becton Dickinson will benefit from the separation of the department. In December, Bank of America analysts wrote that "the total of the parts is getting wider and not ignored", and separating the business from other groups may increase the value by 30 %.
The field side of the co -founder Jeff Smith is one of the most famous radical investors in Wall Street. Some of its highly anticipated advertising series for technology companies Salesforce and Tinder's parents. There are more than $ 9 billion in management assets on the side side.
Recently, the fund has established multiple positions in the field of health care. In October, Starboard announced that it had a share price of the stock price of Pharmaceutical Company Pfizer's shares of PFIZER company, and the company suffered a decline in the stock price after developing the most successful COVID-19-19-19 vaccine.
Hedge funds also revealed its shares in Kenvue in the same month. Kenvue is the consumer health group behind Tylenol, which is separated from Johnson and Johnson. Excited investors later nominated five directors of the board of directors.
The huge group, including Honeywell and London, listed on the London, struggle to break up with shareholders who asked to break up. Investors firmly believed that some companies value the entire combination.
Becton Dickinson has previously separated the business department. The Group emitted Embcta, a diabetic equipment manufacturer in April 2022, but the company's stock has been struggling to a separate business. Since its listing, its stock price has fallen by about 60 %.
Tom Polen, chairman and CEO of Becton Dickinson, said at a conference in September: "We always evaluate our investment portfolio, and we have been looking for the reason for creating the largest shareholder value." Out.
"We always read and say... Are we the best owner of this business? I mean, this is the key issue."